Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesProtagonist Therapeutics Inc

Protagonist Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
136.26 USD 0.36 ( 0.26%)
Last update at 2026-11-10T21:00:00Z
VOLUME
500052
Market Cap
9279.17M
P/E
139.22

Momentum Score

…

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
133.36
Low
137.97
High
52 Week Price Range
58.91
Low
160.81
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
135.90
Dividend Yield
-
Revenue TTM
281.99M
Revenue Per Share
4.36
Gross Profit TTM
281.99M
Debt / Equity
0.02
ROE
10.99%
Net Debt
-118.07M
ROCE
-20.71%
Diluted EPS TTM
1.03

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -129.31M 279.41M -78.95M -127.39M -125.55M
Net income -130.15M 275.19M -78.95M -123.41M -122.63M
Selling general administrative 44.85M 43.46M 33.49M 31.74M 27.20M
Gross profit 44.79M 434.43M 60.00M 26.58M 27.36M
Reconciled depreciation 1.28M 2.90M 3.32M 3.37M 2.77M
Ebit -129.31M 279.41M -78.95M -134.74M -125.84M
Ebitda -128.09M 280.23M -75.64M -131.37M -125.55M
Depreciation and amortization 1.23M 0.83M 3.31M 3.37M 0.29M
Non operating income net other - - - 3.98M 0.29M
Operating income -158.13M 252.84M -93.65M -131.37M -125.84M
Other operating expenses 204.14M 181.59M 153.65M 157.95M 153.20M
Interest expense - - - 3.37M 2.48M
Tax provision 0.84M 4.22M 0.00M 0.00M 0.00M
Interest income 28.79M 26.32M 12.91M 4.06M 0.44M
Net interest income 28.79M 26.32M 12.91M 4.06M 0.44M
Income tax expense 0.84M 4.22M -14.90M -3.98M -2.92M
Total revenue 46.02M 434.43M 60.00M 26.58M 27.36M
Total operating expenses 202.92M 181.59M 153.65M 157.95M 153.20M
Cost of revenue 1.23M 2.96M 3.31M - -
Total other income expense net 28.82M 26.57M 14.70M 3.98M 0.29M
Net income from continuing ops -130.15M 275.19M -140.48M -127.39M -125.55M
Net income applicable to common shares - - - -127.39M -125.55M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 669.89M 744.73M 357.95M 247.93M 347.69M
Other current assets 5.71M 4.24M 13.96M 0.04M 0.97M
Total liab 55.19M 69.43M 21.27M 784.68M 47.67M
Total stockholder equity 614.71M 675.29M 336.68M -536.75M -409.36M
Other current liab 28.27M 23.69M 19.36M 25.02M 38.62M
Common stock 0.00M 0.00M 0.00M - -
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -470.67M -340.52M -615.71M -536.75M -409.36M
Other assets - - - 0.23M 0.23M
Cash 128.39M 97.25M 186.73M 125.74M 123.67M
Total current liabilities 45.44M 47.40M 21.27M 31.18M 44.02M
Current deferred revenue 9.55M 18.89M 0.00M - 1.60M
Net debt -118.07M -86.38M -185.59M -122.09M -117.81M
Short term debt 2.28M 0.51M 1.14M 2.52M 2.20M
Short long term debt total 10.32M 10.87M 1.14M 3.66M 5.86M
Other stockholder equity 1084.74M 1015.90M 952.49M 0.36M 0.30M
Property plant equipment - - - 1.56M 6.73M
Total current assets 577.57M 591.64M 355.58M 237.35M 340.74M
Long term investments 78.64M 140.25M - - 0.00M
Net tangible assets - - - 215.61M 300.02M
Short term investments 438.97M 321.66M 154.89M 111.61M 203.24M
Net receivables 4.50M 168.49M 10.33M 0.05M 4.36M
Inventory - - -10.33M -0.09M 8.50M
Accounts payable 5.34M 1.61M 0.77M 3.64M 1.60M
Accumulated other comprehensive income 0.64M -0.08M -0.10M -0.36M -0.30M
Retained earnings total equity - - - -536.75M -409.36M
Non currrent assets other 78.92M 0.23M 0.23M 5.95M 0.23M
Non current assets total 92.32M 153.08M 2.37M 10.57M 6.96M
Capital lease obligations 10.32M 10.87M 1.14M 3.66M 5.86M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -47.74M -299.48M 25.96M 92.26M -14.76M
Change to liabilities - - - -11.50M -14.27M
Total cashflows from investing activities -49.33M -299.48M -39.26M 91.47M -15.86M
Net borrowings - - - 14.55M -
Total cash from financing activities 22.86M 25.85M 170.48M 18.84M 129.92M
Change to operating activities - - - -9.77M 10.21M
Net income -130.15M 275.19M -78.95M -127.39M -125.55M
Change in cash 31.14M -89.48M 60.98M 2.08M 6.07M
Begin period cash flow 97.25M 186.95M 125.97M 123.89M 117.82M
End period cash flow 128.39M 97.47M 186.95M 125.97M 123.89M
Total cash from operating activities 57.67M 184.15M -70.24M -108.14M -107.86M
Issuance of capital stock 0.00M 0.00M 132.09M 14.55M 123.83M
Depreciation 1.28M 2.90M 3.31M 3.37M 2.77M
Other cashflows from investing activities -49.33M - - - -
Change to inventory - - -9.52M - -
Change to account receivables 164.88M -155.00M -9.99M 1.56M 0.86M
Sale purchase of stock - - -0.77M 4.45M 130.11M
Other cashflows from financing activities -0.48M -0.60M 38.38M 4.29M 6.09M
Change to netincome - - - 24.20M 18.10M
Capital expenditures 1.59M 1.35M 0.61M 0.80M 1.10M
Change receivables - - - 1.56M 0.86M
Cash flows other operating - - - 4.51M -17.96M
Cash and cash equivalents changes - - - 2.17M 6.20M
Change in working capital 146.21M -122.61M -19.51M -7.77M -3.31M
Stock based compensation 45.97M 37.55M 29.29M 24.20M 16.39M
Other non cash items -5.64M -8.88M -4.38M -0.55M 1.83M
Free cash flow 56.08M 182.80M -70.84M -108.93M -108.97M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PTGX
Protagonist Therapeutics Inc		 0.36
0.26%		 136.26 139.22 36.90 32.91 11.04 30.20 142.19
NVO
Novo Nordisk A/S		 -0.68
1.64%		 40.70 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.02
0.55%		 547.85 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -
-%		 916.06 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

7707 Gateway Boulevard, Newark, CA, United States, 94560

510 474 0170

https://www.protagonist-inc.com

141

Name Title Year Born
Dr. Dinesh V. Patel Ph.D. CEO, Pres, Sec. & Director 1957
Dr. David Y. Liu Ph.D. Chief R&D Strategy Officer 1950
Dr. Suneel K. Gupta Ph.D. Chief Devel. Officer 1958
Dr. Richard S. Shames Clinical Advisor 1960
Mr. Asif Ali Exec. VP & Chief Financial Officer NA
Mr. Mohammad Masjedizadeh Exec. VP & CTO NA
Mr. Matthew M. Gosling Exec. VP & Gen. Counsel 1971
Ms. Carena Spivey Exec. Director of HR NA
Dr. Ashok Bhandari Ph.D. Sr. VP of Discovery Chemistry & Process Research 1964
Dr. Scott Eric Plevy M.D. Exec. VP and Therapeutic Head of Gastroenterology NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DRUG
CAD 32.00
+23.08%
CHR
CAD 35.50
+7.80%
HG
CAD 4.77
+7.19%
QTWO
CAD 1.73
+7.14%
PET
CAD 23.03
+7.02%
MUX
CAD 18.80
-17.69%
URE
CAD 0.96
-15.04%
WELL
CAD 3.62
-14.82%
ITH
CAD 2.01
-10.67%
SGML
CAD 7.52
-9.94%

Equity Sectors*

  • Basic Materials

    -3.56%

  • Communication Services

    +0.11%

  • Consumer Cyclical

    -0.57%

  • Consumer Defensive

    -0.30%

  • Energy

    +0.19%

  • Financial Services

    -0.06%

  • Healthcare

    -0.37%

  • Industrials

    -0.81%

  • Real Estate

    -0.85%

  • Technology

    -0.12%

  • Utilities

    -0.11%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…